← Leaderboards
Amy K Barczak
Massachusetts General Hospital
$6,060,280
Attributed
$7,767,423
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,767,423 · 6
By mechanism
R01$5,742,900 · 2
R21$1,339,098 · 3
K08$685,425 · 1
Top collaborators
- Jonathan Li3 shared
- Mark J Siedner3 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Sara Barmettler$1,093,926
- Ruxandra F Sirbulescu$2,281,018
- Sandra Orsulic$4,151,521
- Huajun Feng$2,435,439
- James F Markmann$21,074,268
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionPlayGeneticFutureBacteriaPathogenesisMycobacterium TuberculosisImmune ResponseTuberculosisTuberculosis TreatmentCellsPathway InteractionsPathogenInfection ControlMolecularMacrophageImmuneRecruitEpidemicAntitubercular AgentsGrowthSmall MoleculeResponseCause Of Death
Grant awards (20)
Characterization of Persistent COVID-19$845,667
R01 · FY2025 · AI
Elucidating the path to type I IFNs in TB infection$622,117
R01 · FY2025 · AI · contact PI
Characterization of Persistent COVID-19$846,387
R01 · FY2024 · AI
Elucidating the path to type I IFNs in TB infection$693,073
R01 · FY2024 · AI · contact PI
Elucidating the path to type I IFNs in TB infection$82,895
R01 · FY2024 · AI · contact PI
Characterization of Persistent COVID-19$868,661
R01 · FY2023 · AI
Elucidating the path to type I IFNs in TB infection$593,860
R01 · FY2023 · AI · contact PI
Elucidating the path to type I IFNs in TB infection$607,300
R01 · FY2022 · AI · contact PI
Elucidating the path to type I IFNs in TB infection$582,940
R01 · FY2021 · AI · contact PI
A proteomic approach to understanding phagosome composition in TB infection$210,000
R21 · FY2021 · AI · contact PI
A proteomic approach to understanding phagosome composition in TB infection$252,000
R21 · FY2020 · AI · contact PI
Targeting MT1-MMP to inhibit pathologic inflammation in TB$182,464
R21 · FY2020 · AI · contact PI
Targeting type I interferon production in TB infection.$248,545
R21 · FY2019 · AI · contact PI
Targeting MT1-MMP to inhibit pathologic inflammation in TB$235,464
R21 · FY2019 · AI · contact PI
Targeting type I interferon production in TB infection.$210,625
R21 · FY2018 · AI · contact PI
Chemical genetic approach to cellular mechanisms of M. tuberculosis virulence.$137,085
K08 · FY2014 · AI · contact PI
Chemical genetic approach to cellular mechanisms of M. tuberculosis virulence.$137,085
K08 · FY2013 · AI · contact PI
Chemical genetic approach to cellular mechanisms of M. tuberculosis virulence.$137,085
K08 · FY2012 · AI · contact PI
Chemical genetic approach to cellular mechanisms of M. tuberculosis virulence.$137,085
K08 · FY2011 · AI · contact PI
Chemical genetic approach to cellular mechanisms of M. tuberculosis virulence.$137,085
K08 · FY2010 · AI · contact PI